Chromocell Therapeutics Q1 GAAP EPS $(0.32) Misses $(0.31) Estimate

Chromocell Therapeutics (AMEX: CHRO) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 41.82 percent increase over losses of $(0.55) per share from the same period last year.